Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ACST 
Acasti Pharma Inc (ACST)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/25/2024: ACST (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -60.48% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/25/2024 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 34.17M USD | Price to earnings Ratio - | 1Y Target Price 7.97 |
Price to earnings Ratio - | 1Y Target Price 7.97 | ||
Volume (30-day avg) 44861 | Beta 1.52 | 52 Weeks Range 1.98 - 3.60 | Updated Date 11/24/2024 |
52 Weeks Range 1.98 - 3.60 | Updated Date 11/24/2024 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.43 |
Earnings Date
Report Date 2024-11-11 | When Before Market | Estimate -0.45 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -11.62% | Return on Equity (TTM) -18.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 10253744 | Price to Sales(TTM) 208.39 |
Enterprise Value 10253744 | Price to Sales(TTM) 208.39 | ||
Enterprise Value to Revenue 5.5 | Enterprise Value to EBITDA -0.56 | Shares Outstanding 10139900 | Shares Floating 4646389 |
Shares Outstanding 10139900 | Shares Floating 4646389 | ||
Percent Insiders 38.39 | Percent Institutions 21.23 |
Analyst Ratings
Rating 4.5 | Target Price 1.96 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Acasti Pharma Inc
Company Overview
History and Background
Acasti Pharma Inc., founded in 2002, is a biopharmaceutical company. It initially focused on cardiovascular diseases and developed CaPre, a krill oil-derived omega-3 fatty acid therapy. The company faced clinical trial setbacks and subsequently shifted its focus to other therapeutic areas and corporate strategies.
Core Business Areas
- Drug Delivery Technologies: Development and licensing of innovative drug delivery technologies. Acasti now focuses on licensing and acquiring pharmaceutical products and technologies.
Leadership and Structure
The leadership team consists of the CEO, CFO, and other key executives. The organizational structure is typical of a small-cap biopharmaceutical company, with functional departments such as research and development, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- Drug Delivery Technology Licensing: Acasti focuses on licensing out its drug delivery technologies, like its novel formulation technology. Specific revenue figures and market share are difficult to ascertain due to the focus being on licensing rather than selling a product directly to consumers. Competitors in this space include drug delivery companies that offer similar formulations. Market share and revenue depends on successful licensing agreements.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with significant investment in research and development. Drug delivery technologies are constantly evolving, with a focus on improving efficacy, safety, and patient convenience.
Positioning
Acasti Pharma Inc is a small-cap biopharmaceutical company seeking to monetize its drug delivery technologies. Its competitive advantage lies in its patented formulations and potential for licensing agreements.
Total Addressable Market (TAM)
The global drug delivery market is estimated at hundreds of billions of dollars. Acasti's positioning depends on securing partnerships and licensing deals. Their position is dependent on the attractiveness of their licensed assets in niche areas of this market.
Upturn SWOT Analysis
Strengths
- Novel drug delivery technologies
- Intellectual property portfolio
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on licensing agreements
- Small market capitalization
- History of failed trials
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Acquisition of promising drug candidates
- Strategic acquisitions to bolster portfolio
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Failure of clinical trials
- Economic downturn affecting investment in biotech
Competitors and Market Share
Key Competitors
- ALNY
- MRNA
- LLY
- PFE
- JNJ
Competitive Landscape
Acasti faces intense competition from larger pharmaceutical companies with more resources. Its success depends on differentiating its drug delivery technologies and securing strategic partnerships.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Acasti's historical growth has been characterized by periods of high expectations followed by clinical trial failures and strategic pivots.
Future Projections: Future growth is dependent on successful licensing agreements and potential acquisitions. Analyst projections are speculative given the company's recent history. No longer available due to the fact it is not publicly traded.
Recent Initiatives: Acasti's recent initiatives include focusing on licensing its drug delivery technologies and exploring strategic acquisitions.
Summary
Acasti Pharma has faced significant challenges, including clinical trial setbacks, but currently pivoted to drug delivery. The company's success hinges on securing licensing agreements. It should also continue to pursue strategic acquisitions. The company faces competition from much larger pharmaceutical players and must establish itself quickly.
Similar Companies
- ALNY
- MRNA
- LLY
- PFE
- JNJ
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Financial news sources
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Acasti Pharma Inc
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 2011-05-06 | CEO & Director Mr. Prashant Kohli | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.acastipharma.com |
Full time employees - | Website https://www.acastipharma.com | ||
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.